Shanghai Yizhong Pharmaceutical Co Ltd. Stock Analysis 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of anti-tumor drugs and related pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 37 full-time employees. The company went IPO on 2021-09-09. The firm's main products include paclitaxel micelles, docetaxel micelles and cabazitaxel micelles. Paclitaxel micelles are products under development that have been submitted for registration and marketing applications, and their indications are non-small cell lung cancer. Docetaxel micelles and cabazitaxel micelles are products under development in the pre-clinical research stage.